Samer Al Hadidi, Assistant professor at UAMS Myeloma Center, shared an article on X:
“Longest follow up of phase III clinical trials in myeloma.
- Median survival >13 years.
- 41% of patients remained disease free and off therapy with fixed-duration therapy in standard-risk MM.
- Myeloma is curable for a subset of patients.”
Long-term follow-up of Total Therapy IV: a phase 3 clinical trial for standard-risk multiple myeloma.
Authors: Samer Al Hadidi
More posts featuring Samer Al Hadidi.